Crisugabalin

Phase 3Small molecule

GGuangdong Provincial People's Hospital

Crisugabalin is one of 122 small molecule programs targeting Neuropathic Pain. It is currently in Phase 3.

Indications

Total Trials

Active Trials

121

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuropathic PainRecruiting

FibromyalgiaActive, not recruiting

EfficacyRecruiting

Neuromyelitis Optica Spectrum Disorders (NMOSD)Not yet recruiting

Neuropathic PainPhase 2

Recruiting

FibromyalgiaPreclinical

Active, not recruiting

EfficacyPhase 1

Recruiting

Neuromyelitis Optica Spectrum Disorders (NMOSD)Phase 3

Not yet recruiting

Competition

Competitive Landscape

139 competitors in Efficacy

#DrugCompanyPhaseTrials

Rayos

RRoxane Laboratories

Phase 3

5 2

Paraplatin

AAvyxa

Phase 3

4 3

Alimta

SShawn Eagle

Phase 3

3 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

3 5

Crisugabalin

GGuangdong Provincial People's Hospital

Phase 3

1 6

Cetaphil

GGalderma R&D

Phase 3

1 7

Levocept

SSebela Women's Health Inc.

Phase 3

1 8

Veracept

SSebela Women's Health Inc.

Phase 3

1 9

Aralen

Sanofi

Preclinical

2 10

Primaquine

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Neuropathic Pain

NCT06766916

Q3 2027

ApprovedActive, not recruiting

PARKINSON DISEASE (disorder)

NCT07483398

N/ARecruiting

Fibromyalgia

NCT07196657

Phase 1Recruiting

Efficacy

NCT07453862

Q4 2027

ApprovedNot yet recruiting

Neuromyelitis Optica Spectrum Disorders (NMOSD)

NCT07699770

Clinical

Trials by Indication[1]

Fibromyalgia1 trial

The Efficacy and Safety of Pregabalin and Crisugabalin in Patients With Fibromyalgia

Recruiting·—·N/A·NCT07196657·1,116 enrolled

Neuropathic Pain1 trial

Crisugabalin for Radiotherapy-Related Neuropathic Pain

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06766916·172 enrolled

Efficacy1 trial

Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety

Recruiting·—·Phase 1·NCT07453862·20 enrolled

PARKINSON DISEASE (Disorder)1 trial

Fficacy and Safety of Crisugabalin on Nociplastic Pain in Patients With Parkinson's Disease (RELIEF-PD): A Multicentre, Double-Blind, Randomised Controlled Trial

Active, not recruiting·GGuangdong Provincial People's Hospital·Approved·NCT07483398·166 enrolled

Rosacea1 trial

Real-World Study of Crisugabalin(HSK16149) for the Treatment of Rosacea

Completed·TThe First Affiliated Hospital with Nanjing Medical University·Preclinical·NCT07606820·30 enrolled

1 more indication

Neuromyelitis Optica Spectrum Disorders (NMOSD)1 trial

Efficacy and Safety of Crisugabalin in Treating Neuropathic Pain Related to Neuromyelitis Optica Spectrum Disorders: a Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled, Exploratory Trial

Not yet recruiting·TTang-Du Hospital·Approved·NCT07699770·110 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Crisugabalin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Crisugabalin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Crisugabalin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangdong Provincial People's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGuangdong Provincial People's Hospital

Crisugabalin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q4 2027

Trials by Indication[1]

Fibromyalgia1 trial

Neuropathic Pain1 trial

Efficacy1 trial

PARKINSON DISEASE (Disorder)1 trial

Rosacea1 trial

Neuromyelitis Optica Spectrum Disorders (NMOSD)1 trial

References

Drug Info

Quick Facts

Related News